Oncopeptides is a clinical development pharmaceutical company. It develops anti-cancer drugs. The Company has created Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma.
Type | Public | |
Founded | 2000 | |
HQ | Stockholm, SE | Map |
Website | oncopeptides.com |
SEK | |
---|---|
Revenue (FY, 2021) | 118.3m |
Gross profit (FY, 2021) | 132.8m |
Net income (FY, 2021) | (1.4b) |
EBITDA (FY, 2021) | (1.4b) |
EBIT (FY, 2021) | (1.4b) |
Market capitalization (12-May-2022) | 627.2m |
Closing stock price (12-May-2022) | 8.3 |
Cash (31-Dec-2021) | 362.2m |
EV | 265.0m |
SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 118.3m | |||
Cost of goods sold | (53.1m) | |||
Gross profit | 10.1m | 8.3m | 132.8m | |
R&D expense | (313.5m) | (546.1m) | (860.9m) | (679.9m) |
SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 19.4m | 66.4m | 54.3m | ||||||
Cost of goods sold | (328.0k) | (2.8m) | (31.6m) | ||||||
Gross profit | 2.2m | 3.3m | 16.1m | 8.3m | (8.3m) | 57.0m | 67.7m | 12.2m | |
R&D expense | (94.9m) | (144.4m) | (152.0m) | (213.5m) | (227.8m) | (193.4m) | (178.5m) | (167.3m) | (149.8m) |
SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 375.6m | 926.2m | 840.3m | 362.2m |
Accounts Receivable | 11.9m | |||
Prepaid Expenses | 14.7m | 44.0m | 32.3m | 12.2m |
Inventories | 8.7m |
SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Cash | 747.5m | 626.8m | 1.1b | 617.8m | 937.8m | 1.3b | 372.5m | 999.4m | 671.3m |
Accounts Receivable | 21.4m | 72.8m | 72.9m | ||||||
Prepaid Expenses | 78.3m | 17.8m | 7.0m | 6.5m | 6.2m | 102.4m | 26.6m | 25.5m | |
Inventories | 11.6m | 22.2m |
SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | (411.0m) | (739.4m) | (1.6b) | (1.4b) |
Depreciation and Amortization | 345.0k | 4.5m | 2.0m | |
Inventories | (429.0k) | |||
Accounts Payable | 9.6m | 55.7m | 55.1m |
SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (121.9m) | (305.6m) | (495.1m) | (296.9m) | (696.2m) | (1.1b) | (347.3m) | (692.2m) | (1.0b) |
Oncopeptides revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED
When was Oncopeptides founded?
Oncopeptides was founded in 2000.
Who are Oncopeptides key executives?
Oncopeptides's key executives are Brian Stuglik, Marty J Duvall and Cecilia Daun Wennborg.
How many employees does Oncopeptides have?
Oncopeptides has 321 employees.
What is Oncopeptides revenue?
Latest Oncopeptides annual revenue is kr118.3 m.
What is Oncopeptides revenue per employee?
Latest Oncopeptides revenue per employee is kr368.5 k.
Who are Oncopeptides competitors?
Competitors of Oncopeptides include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.
Where is Oncopeptides headquarters?
Oncopeptides headquarters is located at 46 Luntmakargatan, Stockholm.
Where are Oncopeptides offices?
Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham.
How many offices does Oncopeptides have?
Oncopeptides has 5 offices.
Receive alerts for 300+ data fields across thousands of companies